Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
DexCom Inc is a medical devices business based in the US. DexCom shares (DXCM) are listed on the NASDAQ and all prices are listed in US Dollars. DexCom employs 6,300 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $75.45 |
|---|---|
| 52-week range | $66.89 - $164.86 |
| 50-day moving average | $88.59 |
| 200-day moving average | $118.36 |
| Wall St. target price | $125.55 |
| PE ratio | 153.8037 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.49 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $75.45 from 2022-06-29
| 1 week (2022-06-24) | -2.86% |
|---|---|
| 1 month (2022-05-28) | N/A |
| 3 months (2022-03-30) | -85.46% |
| 6 months (2021-12-31) | -85.95% |
| 1 year (2021-07-01) | -82.32% |
|---|---|
| 2 years (2020-07-01) | -81.15% |
| 3 years (2019-07-01) | 151.43 |
| 5 years (2017-06-30) | 312.58% |
Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 154x. In other words, DexCom shares trade at around 154x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 7.561. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $377.4 million.
The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.6 billion |
|---|---|
| Operating margin TTM | 10.79% |
| Gross profit TTM | $1.7 billion |
| Return on assets TTM | 3.67% |
| Return on equity TTM | 9.55% |
| Profit margin | 7.6% |
| Book value | $5.58 |
| Market capitalisation | $29.5 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 10.43/100
DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 17.04/100
DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.2/100
DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.
DexCom Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.18 |
|---|---|
| Total ESG percentile | 50.12 |
| Environmental score | 10.43 |
| Environmental score percentile | 6 |
| Social score | 17.04 |
| Social score percentile | 6 |
| Governance score | 13.2 |
| Governance score percentile | 6 |
| Level of controversy | 2 |
We're not expecting DexCom to pay a dividend over the next 12 months.
DexCom's shares were split on a 4:1 basis on 12 June 2022. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your DexCom shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for DexCom shares which in turn could have impacted DexCom's share price.
Over the last 12 months, DexCom's shares have ranged in value from as little as $66.8925 up to $164.8625. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 1.0653. This would suggest that DexCom's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
